Xintela publishes positive preclinical results from XSTEM treatment of ARDS

Results from Xintela’s preclinical study with XSTEM® for the treatment of ARDS (Acute Respiratory Distress Syndrome) have been published in the journal Respiratory Research. The results show that XSTEM has a therapeutic effect and provides more stable blood circulation, reduced lung tissue damage and reduced blood clotting compared to placebo. Xintela has previously announced that […]

Xintela’s clinical study with XSTEM for knee osteoarthritis makes good progress

Xintela is conducting a first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis in Australia where three different dose levels of the stem cell product XSTEM® are being tested. The primary goal of the study is to show that XSTEM is safe but also to investigate preliminary efficacy signals. The treatment of 16 patients […]

Xintela AB Interim Report January – March 2023

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 15,843 (loss: 16,383).Loss per share* was SEK 0.05 (loss: 0.18). First quarter 2023 for the parent companyIncome amounted to TSEK 0 (0).Loss before […]

Communiqué from the Annual General Meeting of Xintela AB (publ)

Today, Friday 12 May 2023, the Annual General Meeting was held in Xintela AB (publ). The following main decisions were made. The decisions were taken unanimously. Profit allocation and decision on discharge from liabilityThe meeting decided, in accordance with the board’s proposal, that no dividend is to be paid for the financial year 2022 and […]

Xintela AB publishes Annual Report 2022

Xintela AB (publ) announces that the Swedish version of the company’s Annual Report for 2022 is published on the company’s website, www.xintela.se. The English version will be published shortly. Link to the annual report:https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical […]

Xintela has started last dose level of XSTEM in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing three different dose levels of the stem cell product XSTEM®. The Safety Review Committee for the clinical study assessed the treatment of the eight patients on the second dose level with XSTEM at the one-month follow-up, concluded the […]

Xintela AB: BioStock Investor Meeting with Xintela

Do not miss Xintela’s presentation at the BioStock Investor Meeting, today March 16 at 10.40 am. The event starts at 10.00 – see the full programme on BioStock’s website or YouTube channel.  CEO Evy Lundgren-Åkerlund will present Xintela at the BioStock Investor Meeting (https://www.biostock.se/investormeetingmarch23/), starting at 10.40 am. This is a press release from BioStock – Connecting […]

Xintela completes dosing of XSTEM second dose level in knee osteoarthritis clinical study

Xintela’s first-in-human study (Phase I/IIa) for the treatment of knee osteoarthritis, being conducted in Australia, is testing 3 different dose levels of the stem cell product XSTEM®. All patients at the second dose level have now been dosed. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. […]

Xintela Year-end report 2022

Summary of the year-end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group Fourth quarter 2022 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 23,384 (loss: 18,013).Loss per share* was SEK 0.09 (loss: 0.20). Twelve months 2022 for the groupIncome […]